feed,title,long_url,short_url
Investors,The Hits Keep Coming For Sarepta. Why Its Latest Setback Creates A 'Dangerous Precedent' For Gene Therapies.,https://www.investors.com/news/technology/sarepta-stock-fda-additional-safety-testing-elevidys-gene-therapy/,
